Drug Discovery

PsiThera Raises $47.5 Million and Appoints Eric Shaff as CEO to Push Oral TNF Small-Molecule Drugs

The Roivant spinout plans to use its QUAISAR platform to speed discovery of small molecules for immune and inflammatory diseases.